APUS · Apimeds Pharmaceuticals US, Inc.
$5.65
+5.00 (+764.84%)
At close · Jul 24
Going-concern doubt
— flagged May 26, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not contain any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed May 26, 2026
Market Cap
$85.27M
Shares
15.09M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-06-30 | 8,754 | $0.93 | $8,141 |
| 2026-06-18 | 297 | $1.31 | $389 |
| 2026-06-17 | 911 | $1.17 | $1,066 |
| 2026-06-16 | 1,278 | $1.34 | $1,713 |
| 2026-06-15 | 210 | $1.28 | $269 |
| 2026-06-12 | 4,259 | $1.25 | $5,324 |
| 2026-06-10 | 101 | $1.31 | $132 |
| 2026-06-08 | 61 | $1.27 | $77 |
| 2026-06-04 | 1,739 | $1.35 | $2,348 |
| 2026-05-14 | 3 | $1.30 | $4 |
| 2026-05-11 | 3,283 | $1.51 | $4,957 |
| 2026-05-08 | 8,390 | $1.45 | $12,166 |
| 2026-05-07 | 25,051 | $1.95 | $48,849 |
| 2026-05-06 | 282,984 | $3.00 | $848,952 |
Showing 1–14 of 14 settlements